Fibrobiologics Inc
FBLG0.259USD
-0.002-0.92%
收盘 12/19, 16:00（美东）报价延迟15分钟
12.48M总市值
亏损市盈率 TTM
关于 Fibrobiologics Inc 公司
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Fibrobiologics Inc简介
公司代码FBLG
公司名称Fibrobiologics Inc
上市日期Jan 31, 2024
CEOO'Heeron (Pete)
员工数量13
证券类型Ordinary Share
年结日Jan 31
公司地址455 E. Medical Center Blvd
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编77598
电话12816715150
网址https://fibrobiologics.com/
公司代码FBLG
上市日期Jan 31, 2024
CEOO'Heeron (Pete)
Fibrobiologics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月14日 周日
更新时间: 12月14日 周日
持股股东
股东类型
持股股东
持股股东
占比
O'Heeron (Peter)
8.88%
Golden Knight Inc LP
8.53%
The Vanguard Group, Inc.
1.85%
Yorkville Advisors Global, LP.
0.77%
Millennium Management LLC
0.67%
其他
79.30%
持股股东
持股股东
占比
O'Heeron (Peter)
8.88%
Golden Knight Inc LP
8.53%
The Vanguard Group, Inc.
1.85%
Yorkville Advisors Global, LP.
0.77%
Millennium Management LLC
0.67%
其他
79.30%
股东类型
持股股东
占比
Individual Investor
9.32%
Corporation
8.53%
Investment Advisor
4.70%
Hedge Fund
1.71%
Investment Advisor/Hedge Fund
1.45%
Research Firm
0.25%
Family Office
0.01%
其他
74.01%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
125
5.16M
16.27%
--
2025Q3
125
5.16M
16.27%
+26.14K
2025Q2
124
5.13M
16.68%
-1.32M
2025Q1
115
6.45M
16.82%
+104.96K
2024Q4
107
5.96M
16.68%
+467.89K
2024Q3
99
5.49M
10.74%
+2.00M
2024Q2
74
3.47M
1.58%
+2.95M
2024Q1
20
483.30K
0.00%
+483.30K
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
O'Heeron (Peter)
5.91M
14.1%
--
--
Apr 21, 2025
Golden Knight Inc LP
2.13M
5.1%
+9.85K
+0.46%
Apr 21, 2025
The Vanguard Group, Inc.
1.23M
2.95%
-186.64K
-13.14%
Jun 30, 2025
Millennium Management LLC
480.64K
1.15%
+480.64K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
715.58K
1.71%
-916.88K
-56.17%
Jun 30, 2025
Cascade Financial Partners, LLC
290.58K
0.69%
+30.50K
+11.73%
Jun 30, 2025
Geode Capital Management, L.L.C.
288.95K
0.69%
-325.69K
-52.99%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Global X Russell 2000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Proshares Ultra Russell 2000
占比0%
Texas Capital Texas Small Cap Equity Index ETF
占比0%
iShares Russell 2000 ETF
占比0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Fibrobiologics Inc的前五大股东是谁？
Fibrobiologics Inc 的前五大股东如下：
O'Heeron (Peter)持有股份：5.91M，占总股份比例：14.10%。
Golden Knight Inc LP持有股份：2.13M，占总股份比例：5.10%。
The Vanguard Group, Inc.持有股份：1.23M，占总股份比例：2.95%。
Millennium Management LLC持有股份：480.64K，占总股份比例：1.15%。
BlackRock Institutional Trust Company, N.A.持有股份：715.58K，占总股份比例：1.71%。
O'Heeron (Peter)持有股份：5.91M，占总股份比例：14.10%。
Golden Knight Inc LP持有股份：2.13M，占总股份比例：5.10%。
The Vanguard Group, Inc.持有股份：1.23M，占总股份比例：2.95%。
Millennium Management LLC持有股份：480.64K，占总股份比例：1.15%。
BlackRock Institutional Trust Company, N.A.持有股份：715.58K，占总股份比例：1.71%。
Fibrobiologics Inc的前三大股东类型是什么？
Fibrobiologics Inc 的前三大股东类型分别是：
O'Heeron (Peter)
Golden Knight Inc LP
The Vanguard Group, Inc.
O'Heeron (Peter)
Golden Knight Inc LP
The Vanguard Group, Inc.
有多少机构持有Fibrobiologics Inc(FBLG)的股份？
截至2025Q4，共有125家机构持有Fibrobiologics Inc的股份，合计持有的股份价值约为5.16M，占公司总股份的16.27%。与2025Q3相比，机构持股有所增加，增幅为--。
哪个业务部门对Fibrobiologics Inc的收入贡献最大？
在--，--业务部门对Fibrobiologics Inc的收入贡献最大，创收--，占总收入的--%。
